c-Abl mediates endothelial apoptosis induced by inhibition of integrins αvβ3 and αvβ5 and by disruption of actin

Blood

Volumn 115, Issue 13, 2010, Pages 2709-2718

  Xu, Jingying ^a   Millard, Melissa ^a   Ren, Xiuhai ^a   Cox, Orla T ^a   Erdreich Epstein, Anat ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALBUMIN; ALPHAVBETA5 INTEGRIN; F ACTIN; GROWTH FACTOR RECEPTOR; LATRUNCULIN A; POLYLYSINE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; VITRONECTIN; VITRONECTIN RECEPTOR;

APOPTOSIS; ARTICLE; CELL SPREADING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

EID: 77950986253     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-223776     Document Type: Article

References (50)

1. Cheresh DA, Stupack DG. Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene. 2008;27(48):6285-6298.
2. Delon I, Brown NH. Integrins and the actin cytoskeleton. Curr Opin Cell Biol. 2007;19(1):43-50.
3. Somanath PR, Ciocea A, Byzova TV. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys. 2009;53(2):53-64.
4. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc Natl Acad Sci U S A. 1996;93(18):9764-9769.
5. Mahabeleshwar GH, Chen J, Feng W, Somanath PR, Razorenova OV, Byzova TV. Integrin affinity modulation in angiogenesis. Cell Cycle. 2008;7(3):335-347.
6. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrintargeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(34):5610-5617.
7. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26(6):919-924. (Pubitemid 351398085)
8. Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV. Integrin signaling is critical for pathological angiogenesis. J Exp Med. 2006;203(11):2495-2507. (Pubitemid 44664619)
9. Strömblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest. 1996;98(2):426-433. (Pubitemid 26255742)
10. Blystone SD. Integrating an integrin: a direct route to actin. Biochim Biophys Acta. 2004;1692(2):47-54.
11. Wiesner S, Legate KR, Fassler R. Integrin-actin interactions. Cell Mol Life Sci. 2005;62(10):1081-1099.
12. Woodring PJ, Hunter T, Wang JY. Inhibition of c-Abl tyrosine kinase activity by filamentous actin. J Biol Chem. 2001;276(29):27104-27110. (Pubitemid 37410618)
13. Woodring PJ, Hunter T, Wang JY. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci. 2003;116(13):2613-2626. (Pubitemid 36857215)
14. Woodring PJ, Litwack ED, O'Leary DD, Lucero GR, Wang JY, Hunter T. Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol. 2002;156(5):879-892. (Pubitemid 34839870)
15. Alavi A, Stupack DG. Cell survival in a three-dimensional matrix. Methods Enzymol. 2007;426:85-101.
16. Erdreich-Epstein A, Tran LB, Bowman NN, et al. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem. 2002;277(51):49531-49537. (Pubitemid 36014391)
17. Erdreich-Epstein A, Tran LB, Cox OT, et al. Endothelial apoptosis induced by inhibition of integrins αvβ3 and αvβ5 involves ceramide metabolic pathways. Blood. 2005;105(11):4353-4361. (Pubitemid 40720781)
18. Sohara Y, Shimada H, Scadeng M, et al. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res. 2003;63(12):3026-3031. (Pubitemid 36735845)
19. Erdreich-Epstein A, Shimada H, Groshen S, et al. Integrins αvβ3 and αvβ5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000;60(3):712-721. (Pubitemid 30094572)
20. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 1994;264(5158):569-571.
21. Byzova TV, Goldman CK, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell. 2000;6(4):851-860.
22. Spector I, Shochet NR, Blasberger D, Kashman Y. Latrunculins - novel marine macrolides that disrupt microfilament organization and affect cell growth: I. Comparison with cytochalasin D. Cell Motil Cytoskeleton. 1989;13(3):127-144. (Pubitemid 19197366)
23. Woodring PJ, Hunter T, Wang JY. Mitotic phosphorylation rescues Abl from F-actin-mediated inhibition. J Biol Chem. 2005;280(11):10318-10325. (Pubitemid 40395888)
24. Yi CR, Rosenberg N. Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein. J Virol. 2007;81(17):9461-9468. (Pubitemid 47311489)
25. Furstoss O, Dorey K, Simon V, Barila D, Superti- Furga G, Roche S. c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J. 2002;21(4):514-524. (Pubitemid 34174033)
26. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399(6738):806-809. (Pubitemid 29293179)
27. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7(2):228-234. (Pubitemid 32148491)
28. Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol. 2005;7(3):278-285. (Pubitemid 40331129)
29. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE. Geometric control of cell life and death. Science. 1997;276(5317):1425-1428. (Pubitemid 27235413)
30. Nottrott S, Schoentaube J, Genth H, Just I, Gerhard R. Clostridium difficile toxin A-induced apoptosis is p53-independent but depends on glucosylation of Rho GTPases. Apoptosis. 2007;12(8):1443-1453. (Pubitemid 46988281)
31. Gourlay CW, Ayscough KR. A role for actin in aging and apoptosis. Biochem Soc Trans. 2005;33(6):1260-1264.
32. Ayscough KR, Stryker J, Pokala N, Sanders M, Crews P, Drubin DG. High rates of actin filament turnover in budding yeast and roles for actin in establishment and maintenance of cell polarity revealed using the actin inhibitor latrunculin-A. J Cell Biol. 1997;137(2):399-416. (Pubitemid 27181293)
33. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 1999; 13(18):2400-2411. (Pubitemid 29453611)
34. Kiely PA, Baillie GS, Barrett R, et al. Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for IGF-I-mediated regulation of focal adhesion kinase (FAK). J Biol Chem. 2009;284(30):20263-20274.
35. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell. 1994;77(1):121-131. (Pubitemid 24184693)
36. Yuan ZM, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci U S A. 1997;94(4):1437-1440. (Pubitemid 27087869)
37. Kain KH, Gooch S, Klemke RL. Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion. Oncogene. 2003;22(38):6071-6080.
38. Holcomb M, Rufini A, Barila D, Klemke RL. Deregulation of proteasome function induces Ablmediated cell death by uncoupling p130CAS and c-CrkII. J Biol Chem. 2006;281(5):2430-2440. (Pubitemid 43845702)
39. Taagepera S, McDonald D, Loeb JE, et al. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci U S A. 1998;95(13):7457-7462. (Pubitemid 28293274)
40. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A. 1996;93(26):15174-15179. (Pubitemid 27009572)
41. Truong T, Sun G, Doorly M,Wang JY, Schwartz MA. Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci U S A. 2003;100(18):10281-10286. (Pubitemid 37071869)
42. Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem. 2000;275(45):35631-35637.
43. Lewis JM, Schwartz MA. Integrins regulate the association and phosphorylation of paxillin by c-Abl. J Biol Chem. 1998;273(23):14225-14230.
44. Mitra S, Beach C, Feng GS, Plattner R. SHP-2 is a novel target of Abl kinases during cell proliferation. J Cell Sci. 2008;121(20):3335-3346.
45. Barilà D, Rufini A, Condo I, et al. Caspase-dependent cleavage of c-Abl contributes to apoptosis. Mol Cell Biol. 2003;23(8):2790-2799.
46. Machuy N, Rajalingam K, Rudel T. Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis. Cell Death Differ. 2004;11(3):290-300. (Pubitemid 38313138)
47. Yan W, Bentley B, Shao R. Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol Biol Cell. 2008;19(5):2278-2288.
48. Langley RR, Fan D, Tsan RZ, et al. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res. 2004;64(11):3727-3730. (Pubitemid 38697277)
49. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008;5(1):e19(123-138). (Pubitemid 351198267)
50. Alvarez AR, Klein A, Castro J, et al. Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J. 2008;22(10):3617-3627.